(Total Views: 714)
Posted On: 06/14/2020 10:36:06 PM
Post# of 154120
approved covid then treat cancer
It occurs to me that if approved for covid in the middle of July, CYDY will be in possession of enough leronlimab doses to treat 30,000 people.
Which 30,000 people will be treated?
Well probably the sickest patients. Probably the ones with serious co-morbidities.
Perhaps some metastatic cancer patients?
Standard course of leronlimab is two shots, one on day zero and one on day fourteen.
In metastatic breast cancer patients, circulating tumor cells (CTCs) drop to zero very quickly, maybe less than fourteen days.
If a metastatic cancer patient is treated with leronlimab for a covid infection, cancer efficacy may be demonstrated.
If 30,000 people are treated for covid after July 15, I wonder how many of those 30,000 will be metastatic cancer patients whose circulating tumor cells drop to zero.
To test cancer efficacy in a covid patient, they also need to screen the patient's cancer for CCR5. I guess cancer tissue samples may not be available for the CCR5 screen.
Perhaps some other leronlimab target, like MS or NASH, has a blood marker that would be influenced within the 28 day window of leronlimab treatment for covid?
It occurs to me that if approved for covid in the middle of July, CYDY will be in possession of enough leronlimab doses to treat 30,000 people.
Which 30,000 people will be treated?
Well probably the sickest patients. Probably the ones with serious co-morbidities.
Perhaps some metastatic cancer patients?
Standard course of leronlimab is two shots, one on day zero and one on day fourteen.
In metastatic breast cancer patients, circulating tumor cells (CTCs) drop to zero very quickly, maybe less than fourteen days.
If a metastatic cancer patient is treated with leronlimab for a covid infection, cancer efficacy may be demonstrated.
If 30,000 people are treated for covid after July 15, I wonder how many of those 30,000 will be metastatic cancer patients whose circulating tumor cells drop to zero.
To test cancer efficacy in a covid patient, they also need to screen the patient's cancer for CCR5. I guess cancer tissue samples may not be available for the CCR5 screen.
Perhaps some other leronlimab target, like MS or NASH, has a blood marker that would be influenced within the 28 day window of leronlimab treatment for covid?
(2)
(0)
